Lotus Eye Hospital & InstituteBOM:532998 -4.38%66 EBITDA Margin % is 7.00% as of Mar. 2026, which is 45% below its 10-year median of 12.77. GuruFocus rates BOM:532998 with a GF Score™ of 66/100 and a GF Value™ of ₹91.85 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Lotus Eye Hospital & Institute ranks worse than 55.41% on this metric.
Lotus Eye Hospital & Institute (BOM:532998) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lotus Eye Hospital & Institute EBITDA Margin % Related Terms
Lotus Eye Hospital & Institute EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Eye Hospital & Institute EBITDA Margin % Chart
BOM:532998 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Lotus Eye Hospital & Institute's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Eye Hospital & Institute EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Lotus Eye Hospital & Institute's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lotus Eye Hospital & Institute's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Eye Hospital & Institute (BOM:532998) has a EBITDA Margin % of 7.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lotus Eye Hospital & Institute and its competitors. This is 45% below median its historical median of 12.77. Over the past decade, Lotus Eye Hospital & Institute's EBITDA Margin % has ranged from 8.48 to 18.99. According to the industry distribution chart, Lotus Eye Hospital & Institute ranks #369 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 55.4%.
Is Lotus Eye Hospital & Institute's EBITDA Margin % too high?
Lotus Eye Hospital & Institute's current EBITDA Margin % of 7.00% is 45% below median its 10-year median of 12.77. Over the past 10 years, this metric has ranged from a low of 8.48 to a high of 18.99. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Lotus Eye Hospital & Institute's value of 7.00% is 31.6% below this industry median. Based on the distribution chart, Lotus Eye Hospital & Institute ranks #369 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Lotus Eye Hospital & Institute has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lotus Eye Hospital & Institute's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Lotus Eye Hospital & Institute ranks #369 out of 666 companies for EBITDA Margin %. This places Lotus Eye Hospital & Institute in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Lotus Eye Hospital & Institute's value of 7.00% is 31.6% below this benchmark. Historically, Lotus Eye Hospital & Institute's own EBITDA Margin % has ranged from 8.48 to 18.99 over the past decade. While the company's 10-year median is 12.77 vs. the industry median of 10.24, Lotus Eye Hospital & Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Eye Hospital & Institute's current EBITDA Margin % of 7.00% is 31.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lotus Eye Hospital & Institute and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Eye Hospital & Institute's current EBITDA Margin % is 7.00%, which is 45% below median its own 10-year median of 12.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Eye Hospital & Institute stock overvalued right now?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute (BOM:532998) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹91.85, compared to a current price of ₹116.85 — trading 27.2% above its estimated fair value. The current EBITDA Margin % is 7.00%, which is 45% below median its 10-year median of 12.77 and 31.6% below the Healthcare Providers & Services industry median of 10.24. Lotus Eye Hospital & Institute's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lotus Eye Hospital & Institute (BOM:532998), the current EBITDA Margin % is 7.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Eye Hospital & Institute (BOM:532998) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute stock appears to be overvalued.
The current stock price of ₹116.85 is trading 27.2% above its estimated GF Value™ of ₹91.85.
GuruFocus considers Lotus Eye Hospital & Institute to be Modestly Overvalued.
Key valuation signals for BOM:532998:
EBITDA Margin %: 7.00% (45% below median its 10-year median of 12.77)
GF Value™: ₹91.85 vs. price of ₹116.85 (27.2% above fair value)
Industry Position: 31.6% below the Healthcare Providers & Services median (#369 of 666)
No single metric tells the full story. See the BOM:532998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Eye Hospital & Institute Business Description
Lotus Eye Hospital & Institute Ltd is an India-based eye care hospital. It is engaged in providing treatment and care for eye diseases and disorders. It offers treatment services for eye conditions like refractive error, retina and uvea, cornea, glaucoma, pediatric, orbit and oculoplasty, neuro-ophthalmology, and binocular vision. In addition, the company also operates an eye bank for functioning eye donation activities. The company mainly operates in India and generates revenue by providing medical services, pharmacy sales, contact lenses, and optical, of which the majority of the revenue is derived from providing segmmedical services.
66GF Score
Get the complete analysis for BOM:532998
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532998 has been successfully added to your 
